Stüve-Wiedemann syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:3206OMIM:601559Q78.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Stüve-Wiedemann syndrome (SWS), also known as Stüve-Wiedemann dysplasia or Schwartz-Jampel syndrome type 2, is a rare congenital skeletal disorder characterized by bowing of the long bones, camptodactyly (permanently bent fingers), and life-threatening episodes of hyperthermia (dangerously elevated body temperature). The condition is caused by mutations in the LIFR gene (leukemia inhibitory factor receptor), which plays a critical role in bone development and autonomic nervous system function. SWS primarily affects the skeletal system, the autonomic nervous system, and the respiratory system. Key clinical features present at birth include short stature, bowed long bones (particularly the femora and tibiae), cortical thickening of long bones, metaphyseal flaring, and joint contractures. Affected infants frequently experience respiratory distress, feeding difficulties, and recurrent episodes of unexplained hyperthermia due to autonomic dysfunction. Smooth tongue, absent or reduced corneal and patellar reflexes, and myotonia may also be observed. Many affected infants die in the first months of life due to respiratory failure or hyperthermic crises. Those who survive infancy may develop progressive scoliosis, spontaneous fractures, and jaw abnormalities. There is currently no cure or disease-specific treatment for Stüve-Wiedemann syndrome. Management is supportive and multidisciplinary, focusing on monitoring and controlling body temperature, respiratory support, nutritional assistance, orthopedic interventions for skeletal complications, and physical therapy. Genetic counseling is recommended for affected families. Early recognition and proactive management of hyperthermic episodes and respiratory complications are critical to improving survival in affected infants.

Also known as:

Clinical phenotype terms— hover any for plain English:

Thickened cortex of long bonesHP:0000935Metaphyseal wideningHP:0003016TrismusHP:0000211Lacrimation abnormalityHP:0000632
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Stüve-Wiedemann syndrome.

View clinical trials →

No actively recruiting trials found for Stüve-Wiedemann syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Stüve-Wiedemann syndrome community →

No specialists are currently listed for Stüve-Wiedemann syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Stüve-Wiedemann syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Stüve-Wiedemann syndromeForum →

No community posts yet. Be the first to share your experience with Stüve-Wiedemann syndrome.

Start the conversation →

Latest news about Stüve-Wiedemann syndrome

No recent news articles for Stüve-Wiedemann syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Stüve-Wiedemann syndrome

What is Stüve-Wiedemann syndrome?

Stüve-Wiedemann syndrome (SWS), also known as Stüve-Wiedemann dysplasia or Schwartz-Jampel syndrome type 2, is a rare congenital skeletal disorder characterized by bowing of the long bones, camptodactyly (permanently bent fingers), and life-threatening episodes of hyperthermia (dangerously elevated body temperature). The condition is caused by mutations in the LIFR gene (leukemia inhibitory factor receptor), which plays a critical role in bone development and autonomic nervous system function. SWS primarily affects the skeletal system, the autonomic nervous system, and the respiratory system.

How is Stüve-Wiedemann syndrome inherited?

Stüve-Wiedemann syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Stüve-Wiedemann syndrome typically begin?

Typical onset of Stüve-Wiedemann syndrome is neonatal. Age of onset can vary across affected individuals.